Loading...
•
Sep 30, 2024
United Therapeutics Q3 2024 Earnings Report
Reported record revenue for a sixth straight quarter, driven by increasing demand for innovative products.
Key Takeaways
United Therapeutics reported a strong third quarter in 2024, with total revenues growing by 23% year-over-year to $748.9 million. The company achieved a $3 billion annual revenue run rate and saw significant growth in Tyvaso revenues. They are anticipating clinical data reads and regulatory events to further propel growth.
Total revenues increased by 23% year-over-year to $748.9 million.
Net income rose by 16% to $309.1 million.
Tyvaso revenues grew by 33% to $433.8 million.
The company is progressing with clinical studies and regulatory filings for future growth.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
United Therapeutics anticipates a multi-year cascade of clinical data reads and regulatory events that should continue to propel growth through the balance of the decade and beyond.
Positive Outlook
- Data expected for the TETON studies in idiopathic pulmonary fibrosis.
- Data expected for ADVANCE OUTCOMES in pulmonary arterial hypertension.
- Data from the miroliverELAP phase 1 study now underway for acute liver failure.
- Potential launch of the UKidney human clinical program.
- Filing of an investigational new drug application for UKidney is expected shortly.
Challenges Ahead
- Forward-looking statements are subject to risks and uncertainties.
- Actual results could differ materially from anticipated results.
- The amount ultimately payable in litigation with Sandoz Inc., if any, could be higher or lower than the current accrual.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...